Pfizer and BioNTech is among the vaccine manufacturers insisting they'll be able to quickly adapt their jabs within 100 days if the Omicron variant spreads.
Data suggests the new strain - first identified in South Africa - brings an increased risk of reinfection.
The World Health Organistation's calling it a "variant of concern".
But Jonathan Ball - a professor of molecular virology - says we shouldn't get ourselves into a "frenzy" just yet.
